SEARCH

SEARCH BY CITATION

References

  • 1
    Krawitt EL. Autoimmune hepatitis. N Engl J Med 1996; 334: 897903.
  • 2
    Park SZ, Nagorney DM, Czaja AJ. Hepatocellular carcinoma in autoimmune hepatitis. Dig Dis Sci 2000; 45: 19448.
  • 3
    Johnson PJ, McFarlane IG, Eddleston ALWF. The natural course and heterogeneity of autoimmune-type chronic active hepatitis. Semin Liver Dis 1991; 11: 18796.
  • 4
    Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 92938.
  • 5
    Czaja AJ, Homburger HA. Autoantibodies in liver disease. Gastroenterology 2001; 120: 23949.
  • 6
    Robertson DAF, Zhang SL, Guy EC, Wright R. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987; 2: 911.
  • 7
    Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991; 337: 11837.
  • 8
    Rahaman SM, Chira P, Koff RS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A. Am J Gastroenterol 1994; 89: 1068.
  • 9
    Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989; 34: 12947.
  • 10
    Berk L, Schalm SW, Heijtink RA. Severe chronic active hepatitis (autoimmune type) mimicked by coinfection of hepatitis C and human immunodeficiency viruses. Gut 1991; 32: 1198200.
  • 11
    Mackie FD, Peakman M, Yun M, et al. Primary and secondary liver/kidney microsomal autoantibody response following infection with hepatitis C virus. Gastroenterology 1994; 106: 16725.
  • 12
    Silva E, Sallie R, Tibbs C, McFarlane I, Johnson P, Williams R. Absence of hepatitis C virus in British patients with type 1 autoimmune chronic active hepatitis — a polymerase chain reaction and serological study. J Hepatol 1993; 19: 2115.
  • 13
    Mitchel LS, Jeffers LJ, Reddy KR, et al. Detection of hepatitis C virus antibody by first and second generation assays and polymerase chain reaction in patients with autoimmune chronic active hepatitis types I, II, and III. Am J Gastroenterol 1993; 88: 102734.
  • 14
    Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991; 88: 13708.
  • 15
    Manns MP, Obermayer-Straub P. Cytochromes P450 and uridine triphosphate-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced, and autoimmune liver disease. Hepatology 1997; 26: 105466.
  • 16
    Choudhuri K, Gregorio GV, Mieli-Vergani G, Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology 1998; 28: 117781.
  • 17
    McFarlane IG. Pathogenesis of autoimmune hepatitis. Biomed Pharmacother 1999; 53: 25563.
  • 18
    Manns MP, Obermayer-Straub P. Triggering factors and immunogenetics of autoimmune hepatitis. In: Moreno-OteroR, Clemente-RicoteG, García-MonzónC, eds. Immunology and the Liver: Autoimmunity. Madrid: Arán Ediciones S.A., 2000.
  • 19
    García-Buey L, García-Monzón C, Rodríguez S, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 17707.
  • 20
    Marazuela M, García-Buey L, González-Fernández B, et al. Thyroid autoimmune disorders in patients with chronic hepatitis C before and during interferon-alpha therapy. Clin Endocrinol (Oxf) 1996; 44: 63542.
  • 21
    Silva MO, Reddy KR, Jeffers LJ, Hill M, Schiff ER. Interferon-induced chronic active hepatitis? Gastroenterology 1991; 101: 8402.
  • 22
    Schattner A. Interferons and autoimmunity. Am J Med Sci 1988; 295: 53244.
  • 23
    García-Buey L, López-Botet M, García-Sánchez A, et al. Variability in the expression of a beta 2-microglobulin epitope on hepatocytes in chronic type C hepatitis on treatment with interferon. Hepatology 1993; 17: 37282.
  • 24
    Nagafuchi Y, Scheuer PJ. Expression of beta 2-microglobulin on hepatocytes in acute and chronic type B hepatitis. Hepatology 1986; 6: 203.
  • 25
    Montano L, Miescher GC, Goodall AH, Wiedmann KH, Janossy G, Thomas HC. Hepatitis B virus and HLA antigen display in the liver during chronic hepatitis B virus infection. Hepatology 1982; 2: 55761.
  • 26
    Ballardini G, Bianchi FB, Mirakian R, Fallani M, Pisi E, Bottazzo GF. HLA-A,B,C, HLA-D/DR and HLA-D/DQ expression on unfixed liver biopsy sections from patients with chronic liver disease. Clin Exp Immunol 1987; 70: 3546.
  • 27
    Lobo-Yeo A, Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Class I and class II major histocompatibility complex antigen expression on hepatocytes: a study in children with liver disease. Hepatology 1990; 12: 22432.
  • 28
    Franco A, Barnaba V, Natali P, Balsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology 1988; 8: 44954.
  • 29
    Chu CM, Shyu WC, Kuo RW, Liaw YF. HLA class I antigen display on hepatocyte membrane in chronic hepatitis B virus infection: its role in the pathogenesis of chronic type B hepatitis. Hepatology 1988; 8: 7127.
  • 30
    Lautenschlager I, Taskinen E, Inkinen K, Lehto VP, Virtanen I, Hayry P. Distribution of the major histocompatibility complex antigens on different cellular components of human liver. Cell Immunol 1984; 85: 191200.
  • 31
    Barbatis C, Woods J, Morton JA, Fleming KA, McMichael A, McGee JO. Immunohistochemical analysis of HLA (A, B, C) antigens in liver disease using a monoclonal antibody. Gut 1981; 22: 98591.
  • 32
    Fukusato T, Gerber MA, Thung SN, Ferrone S, Schaffner F. Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol 1986; 123: 26470.
  • 33
    Van den Oord JJ, De Vos R, Desmet VJ. HLA expression in liver disease. Prog Liver Dis 1990; 9: 7388.
  • 34
    García-Monzón C, Majano PL, Solís JA, et al. Intrahepatic enhanced expression of beta2-microglobulin conformational epitope in acute liver allograft rejection: evidence of modulation by glucocorticoids. Dig Dis Sci 1998; 43: 175562.
  • 35
    Dienes HP, Autschbach F, Gerber MA. Ultrastructural lesion in autoimmune hepatitis and steps of the immune response in liver tissue. Semin Liver Dis 1991; 11: 197204.
  • 36
    Mieli-Vergani G, Vergani D. Immunological liver diseases in children. Semin Liver Dis 1998; 18: 2719.
  • 37
    Treichel U, McFarlane BM, Seki T, et al. Demographics of anti-asialoglycoprotein receptor autoantibodies in autoimmune hepatitis. Gastroenterology 1994; 107: 799804.
  • 38
    Treichel U, Portalla T, Hess G, Manns M, Meyer zum Büschenfelde KH. Autoantibodies to human asialoglycoprotein receptor in autoimmune-type chronic active hepatitis. Hepatology 1990; 11: 60612.
  • 39
    Stockert RJ. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol Rev 1995; 75: 591609.
  • 40
    McFarlane BM, Sipos J, Gove CD, McFarlane IG, Williams R. Antibodies against the hepatic asialoglycoprotein receptor perfused in situ preferentially attach to periportal liver cells in the rat. Hepatology 1990; 11: 40815.
  • 41
    Wesierska-Gadek J, Grimm R, Hitchman E, Penner E. Members of the glutathione S-transferase gene family are antigens in autoimmune hepatitis. Gastroenterology 1998; 114: 32935.
  • 42
    McFarlane IG. Lessons about antibodies in autoimmune hepatitis. Lancet 2000; 355: 14756.
  • 43
    Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000; 355: 15105.
  • 44
    Costa M, Rodriguez-Sanchez JL, Czaja AJ, Gelpi C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis. Clin Exp Immunol 2000; 121: 36474.
  • 45
    Martini E, Abuaf N, Cavalli F, et al. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2. Hepatology 1988; 8: 16626.
  • 46
    Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998; 42: 7216.
  • 47
    Pelli N, Fensom AH, Slade C, Boa F, Mieli-Vergani G, Vergani D. Argininosuccinate lyase: a new autoantigen in liver disease. Clin Exp Immunol 1998; 114: 45561.
  • 48
    Lapierre P, Hajoui O, Homberg JC, Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognised by sera of patients with autoimmune hepatitis. Gastroenterology 1999; 116: 6439.
  • 49
    García-Monzón C, García-Buey L, García-Sánchez A, Pajares JM, Moreno-Otero R. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b. Gastroenterology 1993; 105: 4629.
  • 50
    Autschbach F, Meuer SC, Moebius U, et al. Hepatocellular expression of lymphocyte function-associated antigen 3 in chronic hepatitis. Hepatology 1991; 14: 22330.
  • 51
    Volpes R, Van Den Oord JJ, Desmet VJ. Immunohistochemical study of adhesion molecules in liver inflammation. Hepatology 1990; 12: 5965.
  • 52
    Moreno-Otero R, García-Monzón C, García-Buey L. Pathogenesis of autoimmune liver diseases. In: ArroyoV, BoschJ, BrugueraM, RodésJ, eds. Therapy in Liver Diseases: The Pathophysiological Basis of Therapy. Barcelona: Masson S.A., 1997: 21929.
  • 53
    Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991; 13: 36475.
  • 54
    Kroemer G, Andreu JL, Gonzalo JA, Gutierrez-Ramos JC, Martinez C. Interleukin-2, autotolerance, and autoimmunity. Adv Immunol 1991; 50: 147235.
  • 55
    Arai KI, Lee F, Miyajima A, Miyatake S, Arai N, Yokota T. Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 1990; 59: 783836.
  • 56
    Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 122431.
    Direct Link:
  • 57
    Castilla A, Prieto J, Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy. N Engl J Med 1991; 324: 93340.
  • 58
    Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 26474.
  • 59
    Al-Janadi M, Al-Wabel A, Raziuddin S. Soluble CD23 and interleukin-4 levels in autoimmune chronic active hepatitis and systemic lupus erythematosus. Clin Immunol Immunopathol 1994; 71: 337.
  • 60
    Schlaak JF, Lohr H, Gallati H, Meyer zum Buschenfelde KH, Fleischer B. Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis. Clin Exp Immunol 1993; 94: 16873.
  • 61
    Nishioji K, Okanoue T, Itoh Y, et al. Increase of chemokine interferon-inducible protein-10 (IP-10) in the serum of patients with autoimmune liver diseases and increase of its mRNA expression in hepatocytes. Clin Exp Immunol 2001; 123: 2719.
  • 62
    Bayer EM, Herr W, Kanzler S, et al. Transforming growth factor-beta1 in autoimmune hepatitis: correlation of liver tissue expression and serum levels with disease activity. J Hepatol 1998; 28: 80311.
  • 63
    Sanz-Cameno P , Medina J, García-Buey L, et al. Enhanced intrahepatic inducible nitric oxide synthase expression and nitrotyrosine accumulation in primary biliary cirrhosis and autoimmune hepatitis. J Hepatol, in press.
  • 64
    García-Monzón C, Sánchez-Madrid F, García-Buey L, García-Arroyo A, García-Sánchez A, Moreno-Otero R. Vascular adhesion molecules expression in viral chronic hepatitis: evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 23141.
  • 65
    Manns MP, Kruger M. Immunogenetics of chronic liver diseases. Gastroenterology 1994; 106: 167697.
  • 66
    Doherty DG, Donaldson PT, Underhill JA, et al. Allelic sequence variation in the HLA class II genes and proteins in patients with autoimmune hepatitis. Hepatology 1994; 19: 60915.
  • 67
    Donaldson P, Doherty D, Underhill J, Williams R. The molecular genetics of autoimmune liver disease. Hepatology 1994; 20: 22539.
  • 68
    Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997; 112: 202835.
  • 69
    Czaja AJ, Strettell MDJ, Thomson LJ, et al. Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis. Hepatology 1997; 25: 31723.
  • 70
    Toda G, Zeniya M, Watanabe F, et al. Present status of autoimmune hepatitis in Japan — correlating the characteristics with international criteria in an area with a high rate of HCV infection. J Hepatol 1997; 26: 120712.
  • 71
    Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000; 174: 2509.
  • 72
    Scully LJ, Toze C, Sengar DPS, et al. Early-onset autoimmune hepatitis is associated with a C4A gene deletion. Gastroenterology 1993; 104: 147884.
  • 73
    Doherty DG, Underhill JA, Donaldson PT, et al. Polymorphism in the human complement C4 genes and genetic susceptibility to autoimmune hepatitis. Autoimmunity 1994; 18: 2439.
  • 74
    Donaldson PT, Manns MP. Immunogenetics of liver disease. In: BircherJ, BenhamouJ-P, McIntyreN, RizzettoM, RodesJ, eds. Oxford Textbook of Clinical Hepatology. Oxford: Oxford University Press, 1999: 17388.
  • 75
    Doherty DG, Penzotti JE, Koelle DM, et al. Structural basis of specificity and degeneracy of T cell recognition: pluriallelic restriction of T cell responses to a peptide antigen involves both specific and promiscuous interactions between the T cell receptor, peptide, and HLA-DR. J Immunol 1998; 161: 352735.
  • 76
    Czaja AJ, Cookson S, Constantini PK, Clare M, Underhill JA, Donaldson PT. Cytokine polymorphisms associated with clinical features and treatment outcome in type 1 autoimmune hepatitis. Gastroenterology 1999; 117: 64552.
  • 77
    Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with anti-liver/kidney microsome antibody type I: a second type of autoimmune hepatitis. Hepatology 1987; 197: 13339.
  • 78
    Manns M, Jentsch M, Mergener K, et al. HLA class I–III in autoimmune hepatitis type 2 and its association with hepatitis C infection (Abstract). J Hepatol 1991; 16: 16.
  • 79
    Lenzi M, Mantovani W, Cataleta M, et al. HLA typing in autoimmune hepatitis (AI-CAH) type 2. J Hepatol 1992; 16: 59.
  • 80
    Czaja AJ. Diagnostics and therapy of autoimmune liver disease. Med Clin N Am 1996; 80: 97394.
  • 81
    Czaja AJ. Drug therapy in the management of type 1 autoimmune hepatitis. Drugs 1999; 57: 4968.
  • 82
    Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 15985.
  • 83
    Soloway RD, Summerskill WHJ, Baggenstoss AH, et al. Clinical, biochemical and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 82033.
  • 84
    Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; I: 7357.
  • 85
    Schalm SW, Korman MG, Summerskill WHJ, et al. Severe chronic active liver disease: prognostic significance of initial morphologic patterns. Am J Dig Dis 1977; 22: 97380.
  • 86
    Davis GL, Czaja AJ, Ludwig J. Development and prognosis of histologic cirrhosis in corticosteroid-treated HBsAg-negative chronic active hepatitis. Gastroenterology 1984; 87: 12227.
  • 87
    Czaja AJ, Wolf AM, Baggenstoss AH. Laboratory assessment of severe chronic active liver disease (CALD): correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 68792.
  • 88
    Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 6227.
  • 89
    Czaja AJ, Ludwig J, Baggenstoss AH, et al. Corticosteroid-treated chronic active hepatitis in remission. Uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304: 59.
  • 90
    Al-Khalidi JA, Czaja AJ. Current concepts in the diagnosis, pathogenesis and treatment of autoimmune hepatitis. Mayo Clin Proc 2001; 76: 123752.
  • 91
    Czaja AJ, Wang KK, Shiels MT, et al. Oral pulse prednisone therapy after relapse of severe autoimmune chronic active hepatitis: a prospective randomized treatment trial evaluating clinical, biochemical and lymphocyte subset responses. J Hepatol 1993; 17: 1806.
  • 92
    Chase WF, Winn RE, Mayes GR. Oral pulse prednisone therapy in the treatment of HbsAg negative chronic active hepatitis. Gastroenterology 1982; 83: 12926.
  • 93
    Brown TE, Ahmed A, Filo RS, et al. The immunosuppressive mechanism of azathioprine: 1. In vitro effect on lymphocyte function in the baboon. Transplantation 1976; 21: 2735.
  • 94
    Summerskill WHJ, Korman MG, Ammon HV, et al. Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared. Gut 1975; 16: 87683.
  • 95
    Czaja AJ. Diagnosis, prognosis and treatment of classical autoimmune chronic active hepatitis. In: KrawittEL, WiesnerRH, eds. Autoimmune Liver Disease. New York: Raven Press, 1991: 14366.
  • 96
    Czaja AJ. Low dose corticosteroid therapy after multiple relapses of severe HbsAg-negative chronic active hepatitis. Hepatology 1990; 11: 10449.
  • 97
    Stellon AJ, Keating JJ, Johnson PJ, et al. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 7814.
  • 98
    Johnson PJ, McFarlane IG, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 95863.
  • 99
    Uribe M, Go VLW, Kluge D. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984; 6: 3315.
  • 100
    Stellon AJ, Davies A, Compston J, et al. Bone loss in autoimmune chronic hepatitis on a maintenance corticosteroid therapy. Gastroenterology 1985; 89: 107883.
  • 101
    Wang KK, Czaja AJ, Beaver SJ, et al. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 3943.
  • 102
    Lewis GP, Jusko WJ, Burke CW, et al. Prednisone side-effects and serum protein levels: a collaborative study. Lancet 1971; 2: 77880.
  • 103
    Heneghan MA, McFarlane IG. Current and novel immunosuppressive therapy for autoimmune hepatitis. Hepatology 2002; 35: 713.
  • 104
    Heneghan MA, Norris SM, O'Grady JG, et al. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97102.
  • 105
    Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood. A 20 year survey. Hepatology 1997; 25: 5417.
  • 106
    Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999; 30: 2227.
  • 107
    Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporin A in children with type 2 autoimmune hepatitis. J Pediatr 1999; 135: 1114.
  • 108
    Hyams JS, Ballow M, Leichtner AM. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 8903.
  • 109
    Person JL, McHutchison JG, Fong TL, Redeker AG. A case of cyclosporine-sensitive, steroid resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 31720.
  • 110
    Sherman KE, Narkewicz M, Pinto PC. Cyclosporine in the management of corticosteroid-resistant type 1 autoimmune chronic active hepatitis. J Hepatol 1994; 21: 10407.
  • 111
    Jackson LD, Song E. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 45961.
  • 112
    Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 2418.
    Direct Link:
  • 113
    Clissold SP, Heel RC. Budesonide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in asthma and rhinitis. Drugs 1984; 28: 485518.
  • 114
    Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 58590.
  • 115
    Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 13126.
  • 116
    Thomson AW. FK-506: profile of an important new immunosuppressant. Transplant Rev 1990; 4: 113.
  • 117
    Van Thiel DH, Wright H, Carroll P, et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 7716.
  • 118
    Richard PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 3715.
  • 119
    Czaja AJ, Manns MP, McFarlane IG, Hoofnagle JH. Autoimmune hepatitis: the investigational and clinical challenges. Hepatology 2000; 31: 1194200.
  • 120
    Nakamura K, Yoneda M, Yokohama S, et al. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol 1998; 13: 4905.
  • 121
    Czaja AJ, Carpenter HA, Lindor KD. Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: a randomized placebo-controlled treatment trial. Hepatology 1999; 30: 13816.
  • 122
    Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 9903.
  • 123
    Kavizler S, Gerken G, Drenes HP, Meyer zum Buschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis — report of three cases. Z Gastroenterol 1997; 35: 5718.
  • 124
    Pratt DS, Flavin DP, Kaplan MM. The successful treatment of autoimmune hepatitis with mercaptopurine after failure with azathioprine. Gastroenterology 1996; 110: 2714.
  • 125
    Rebollo Bernardez J, Cifuentes Mimoso C, Pinar Moreno A, et al. Deflazacort for long-term maintenance of remission in type I autoimmune hepatitis. Rev Esp Enferm Dig 1999; 91: 6308.
  • 126
    Hegarty JE, Nouri-Aria KT, Eddleston ALWF, et al. Controlled trial of a thymic hormone extract (Thymostimulin) in ‘autoimmune’ chronic active hepatitis. Gut 1977; 25: 27983.
  • 127
    Stern RB, Wilkinson SP, Howorth PJN, et al. Controlled trial of synthetic d-penicillamine and prednisone in maintenance therapy for active chronic hepatitis. Gut 1977; 18: 1922.
  • 128
    Bar-Meir S, Halpern Z, Gutman M, et al. Effect of (+)-cyanidanol-3 on chronic active hepatitis: a double blind controlled trial. Gut 1985; 26: 9759.
  • 129
    Lohse AW, Dienes HP, Meyer zum Buschenfelde KH. Suppression of murine experimental autoimmune hepatitis by T-cell vaccination or immunosuppression. Hepatology 1998; 27: 153643.
  • 130
    Wardrop RM 3rd, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res 1999; 48: 10619.
  • 131
    Utku N, Heinemann T, Tullius SG, et al. Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity 1998; 9: 50918.
  • 132
    Sánchez-Urdazpal L, Czaja AJ, Van Hoek B, Krom RAF, Wiesner RH. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 21521.
  • 133
    Ratziu U, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999; 30: 13141.
  • 134
    Ayata G, Gordon FD, Lewis WD, et al. Liver transplantation for autoimmune hepatitis: a long-term pathologic study. Hepatology 2000; 32: 18592.
  • 135
    Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001; 7: 30210.
  • 136
    Reich DJ, Fiel I, Guarrera JV, et al. Liver transplantation for autoimmune hepatitis. Hepatology 2000; 32: 693700.
  • 137
    Birnbaum AH, Benkar KJ, Prittman NS, McFarlane-Ferreira Y, Rosh JR, Leleiko NS. Recurrence of autoimmune hepatitis in children after liver transplantation. J Pediatr Gastroenterol Nutr 1997; 25: 205.
  • 138
    Prados E, Cuervas-Mons V, De La Mata M, et al. Outcome of autoimme hepatitis after liver transplantation. Transplantation 1998; 66: 164550.